ClinicalTrials.gg
CompletedNCT05020652Updated Jun 2, 2026

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

A Phase 2 interventional study of TQ05105 tablets and Hydroxycarbamide tablets in Moderate and High Risk Myelofibrosis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies in Lymphoma, Follicular with a site in China — 75 open to participants now, 88 under way, 20 of them phase 3. Lymphoma, Follicular · China.

Enrollment
61st of 132
107 · median 93
Started
2021
with 9 others
Phase 2
41 of 147
23 open now
Registered
69th of 147
by date

Among the 147 studies in Lymphoma, Follicular with a site in China, this one is the 61st largest by enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2021, is one of 41 in phase 2, and was the 69th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

75 of the 147 studies in Lymphoma, Follicular with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Lymphoma, Follicular with a site in China, or all of them as a file.
02

Study summary

Q05105 tablet is a Janus kinase 2 (JAK2) inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis

03

Conditions studied

  • Moderate and High Risk Myelofibrosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects volunteered to join the study and signed , with good compliance;
  2. Age: 18-75 years old (when signing the informed consent form); (ECoG) Performance Status (PS) score: 0-2; The expected survival time is more than 24 weeks;
  3. Primary Myelofibrosis (PMF) was diagnosed according to World Health Organization (WHO) standard (2016 Edition), or Post Polycythemia Vera(PV)-MF or Post Essential Thrombocythemia (ET)-MF was diagnosed according to International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) standard; JAK2 mutation or not was included in the study;
  4. According to Dynamic International Prognostic Scoring System (DIPSS) prognosis grading criteria, the patients with myelofibrosis were assessed as medium risk (including medium risk-1, medium risk-2) or high risk;
  5. Splenomegaly: palpate the splenic margin at least 5cm below the ribs (the distance from the costal margin to the farthest point of splenic protrusion);
  6. Peripheral blood primordial cells ≤ 10%;
  7. If antifibrotic treatment for myelofibrosis is ongoing before screening, hydroxyurea, any immunomodulators such as thalidomide, short-acting interferons, androgenic drugs, and any (such as prednisone > 10mg/day or equivalent strength ) must be discontinued for at least 2 weeks before randomization; long-acting interferons and erythropoietin must be discontinued for at least 4 weeks before randomization;
  8. No growth factor, colony stimulating factor, thrombopoietin or transfusion was received within 2 weeks before the examination, and (Hgb) ≥ 80g / L, platelet count (PLT) ≥ 100 within 7 days before the random date × 10\^9 / L and neutrophil absolute value (neut) ≥ 1.0 × 10\^9/L;
  9. The main organs were functional 7 days before the random date, which was in accordance with the following criteria: Total (TBIL) was less than 2 times the value (ULN); (ALT) and Aspartate aminotransferase (AST) were less than 2.5 times of ULN; Serum creatinine (Cr) \< 1.5 times of ULN or rate (Ccr) ≥ 50ml/min; The blood coagulation function should be checked in accordance with: (PT), activated partial thromboplastin time (APTT), international standardized ratio (INR) \< 1.5 × ULN (not anticoagulant treatment); (LVEF) evaluated by color Doppler ultrasonography ≥ 50%;
  10. Female subjects of childbearing age should agree to use measures (such as intrauterine device, contraceptive or condom) during the study period and within 6 months after the end of the study; The serum pregnancy test was negative within 7 days before the date of randomization and must be non lactating subjects; Male subjects should agree to use contraception during the study period and within 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  1. Those who have received stem cell transplantation in the past, or autologous stem cell transplantation within 3 months before the random date, or recently planned stem cell transplantation;
  2. Patients who have received JAK inhibitors in the past;
  3. Those who had undergone splenectomy or received splenic radiotherapy within 6 months before the date of randomization (including internal and external radiotherapy);
  4. Other were present or present within 3 years before the date of randomization. The following two cases can be included: other malignant tumors treated by single operation have achieved 5-year disease-free survival (DFS) in a row; Cured cervical carcinoma in situ, non melanoma skin cancer and superficial bladder tumor [ta (non-invasive tumor), tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
  5. Patients with multiple factors (such as inability to swallow, postoperative gastrointestinal resection, acute and chronic diarrhea, intestinal obstruction, etc.) affecting oral or absorption of drugs;
  6. Non hematological toxicity caused by previous treatment did not return to ≤ 1 (excluding alopecia);
  7. Patients who received major surgical treatment or had obvious traumatic injury within 4 weeks before the date of randomization;
  8. At present, there are congenital bleeding or coagulation diseases, or are using anticoagulant therapy;
  9. Arteriovenous thrombotic events occurred within 6 months before the random date, such as cerebrovascular accident (including , cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism;
  10. A history of psychotropic substance abuse or mental disorder;
  11. Active or uncontrolled severe infection (≥ (CTCAE)2 infection);
  12. Virus (HBV) DNA≥; antibody positive and Hepatitis C Virus (HCV) RNA ≥ ULN;
  13. Myocardial ischemia or myocardial infarction, arrhythmia, prolongation (corrected QT interval (QTc) ≥ 450 ms for male, QTc ≥ 470 ms for female) and congestive heart failure ( classification) of grade 2 or above;
  14. Blood pressure control is not ideal (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg);
  15. Renal failure requires hemodialysis or peritoneal dialysis;
  16. Newly diagnosed pulmonary fibrosis or drug-related interstitial lung disease within 3 months before the date of randomization;
  17. History of immunodeficiency, including (HIV) positive or other acquired or congenital immunodeficiency diseases, or organ transplantation;
  18. Patients with epilepsy and need treatment;
  19. Within 4 weeks prior to the random date, the patient had received chemotherapy, radiotherapy or other anti-cancer treatments (except as stipulated in item 7 of the inclusion criteria);
  20. Within 2 weeks before the date of randomization, he received Chinese patent medicines (including compound cantharis capsule, Kang'ai injection, kang'laite capsule / injection, Aidi injection, Brucea javanica oil injection / capsule, Xiaoaiping tablet / injection, cinobufagin capsule, etc.) with anti-tumor indications specified in nmpa approved drug instructions;
  21. Uncontrolled pleural effusion, pericardial effusion or ascites;
  22. Patients with central nervous system involvement;
  23. There was a history of inoculation within 4 weeks before the date of randomization or live attenuated vaccine inoculation was planned during the study period;
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    TQ05105 tablets + Hydroxyurea blank tablets

    Take TQ05105 Tablets + Hydroxyurea blank tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration

    Drug: TQ05105 tablets

  • Active comparator
    TQ05105 blank tablets + Hydroxyurea tablets

    Take TQ05105 blank tablets + Hydroxyurea tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration

    Drug: Hydroxycarbamide tablets

Interventions

  • TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.

  • Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.

06

What researchers measure

Primary outcomes

  1. Spleen Volume was Reduced by more than 35% from baseline(SVR35) assessed by Independent Review Committee (IRC)

    Proportion of subjects whose spleen volume was reduced by more than 35% from baseline at the end of week 24 of IRC assessment (SVR35)

    Time frame: up to 24 weeks

Secondary outcomes

  1. SVR35 assessed by the researchers and objective response rate (ORR)

    Proportion of subjects whose spleen volume was reduced by more than 35% from baseline to the end of the 24th week assessed by the researchers and ORR

    Time frame: up to 24 weeks

  2. optimal response rate of splenic response

    Proportion of subjects with at least one reduction in spleen volume ≥ 35% from baseline.

    Time frame: up to 120 weeks

  3. onset time of splenic response

    The time between the date of randomization and the date when the spleen volume decreased ≥ 35% from the baseline for the first time.

    Time frame: up to 120 weeks

  4. Duration of Maintenance of a Least 35% Reduction in Spleen Volume(DoMSR)

    Duration of spleen volume reduction ≥ 35% from baseline (domsr): the time between the date when the spleen volume reduction ≥ 35% from baseline occurs for the first time and the date when the spleen volume reduction \< 35% from baseline.

    Time frame: up to 120 weeks

  5. the proportion of subjects whose total symptom score of Myeloproliferative neoplasm- Symptom Assessment Form- Total Symptom Score(MPN-SAF TSS) decreased by more than 50% compared with baseline

    At the 24th week, the proportion of subjects whose total symptom score of MPN-SAF TSS) decreased by more than 50% compared with baseline.

    Time frame: up to 24 weeks

  6. The total symptom score of MPN-SAF TSS decreased compared with baseline

    The total symptom score of MPN-SAF TSS decreased compared with baseline;

    Time frame: up to 24 weeks

  7. Progression-free survival (PFS)

    The interval from the random date to the date of occurrence of any of the following events, whichever occurs first: ① the spleen volume increases by ≥ 25% compared with the lowest value during the treatment period (including the screening period); ② Death from any cause; ③ Start other anti-MF treatments;

    Time frame: up to 120 weeks

  8. Leukemia free survival (LFS)

    The time interval between the random date and the date of any of the following events, whichever occurs first, shall prevail: ① the date when the first bone marrow smear showed that the number of primordial cells was more than or equal to 20%; ② The first peripheral blood smear showed that the number of primordial cells was more than or equal to 20% and the absolute value of primordial cells was more than or equal to 1% × 10\^9 / L for at least 2 weeks; ③ Death from any cause;

    Time frame: up to 120 weeks

  9. Overall survival (OS)

    The time interval between the random date and death from any cause

    Time frame: up to 120 weeks

  10. The incidence and severity of adverse events (AEs) occurred during the study

    The incidence and severity of AEs occurred during the study

    Time frame: up to 120 weeks

07

Study locations

4 sites
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100005, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510055, China
  • West China School of Medicine / West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College
    Tianjin, Tianjin Municipality 300020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Oct 2023, 23 months.

Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 23 months is below that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2021
First posted
Aug 25, 2021
StartActual
Nov 11, 2021
Primary completionActual
Oct 15, 2023
CompletionActual
Dec 26, 2023
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05020652
Responsible party
Sponsor
First posted
Aug 25, 2021
Start date
Nov 11, 2021
Primary completion
Oct 15, 2023
Completion
Dec 26, 2023
Last update
Jun 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion